Takeda, Zedira and Dr. Falk Pharma inked a collaboration and licensing agreement to develop TAK-227, an investigational therapy for patients with celiac disease, an autoimmune disorder characterized by inability to tolerate gluten. The therapy currently is undergoing a phase 2b trial. Read More

Eli Lilly plans to further expand into gene therapies with the $487 million purchase of Massachusetts-based biotech Akouos, a company developing gene treatments for hearing loss. Read More

Nimbus Therapeutics could snag up to $469 million for developing a line of novel metabolic disorder therapeutics for Eli Lilly. Read More

AstraZeneca is spending $68 million to acquire LogicBio Therapeutics, a move that brings two innovative gene editing platforms to the pharma giant’s fold. Read More